DrugMar 8, 2023
BusPIRone Hydrochloride Tablets USP, 5 mg recall — FDA D-0376-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
Latest records
Latest recalls — page 290
The newest recall records with useful source details are listed here.
DrugMar 8, 2023
rOPINIRole Tablets USP 0.25 mg*, 100-count bottle recall — FDA D-0425-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
Pirfenidone Tablets 267 mg 90-count bottle x3/Carton recall — FDA D-0419-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
Atorvastatin Calcium Tablets USP 40 mg* recall — FDA D-0373-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
Volt Candy Wholesale Club PrimeZEN Black 6000 capsule, 2000mg, Male Sexual Performance recall — FDA D-0453-2023
Marketed Without An Approved NDA/ANDA: FDA analysis found the product to be tainted with undeclared sildenafil and tadalafil, ingredients found in FDA approved products for the treatment of…
Class IFDA: TerminatedVolt Candy Wholesale Club
DrugMar 8, 2023
DuPont Nutrition USA BD-102 NF, Microcrystalline Cellulose, NF, Ph recall — FDA D-0352-2023
Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.
Class IIIFDA: TerminatedDuPont Nutrition USA, Inc.
DrugMar 8, 2023
Montelukast Sodium Tablets, USP, 10 mg* recall — FDA D-0400-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
BusPIRone Hydrochloride Tablets USP 30 mg, 60-count bottle recall — FDA D-0379-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
Atorvastatin Calcium Tablets USP 80 mg* recall — FDA D-0374-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
Levothyroxine Sodium Tablets, USP 112 mcg, 90 tablets per bottle recall — FDA D-0353-2023
Sub-Potent Drug: Out of specification for assay at the 24 month interval.
Class IIFDA: TerminatedAlvogen, Inc.
DrugMar 8, 2023
Dofetilide Capsules 250 mcg (0.25 mg) 60-count bottle recall — FDA D-0384-2023
CGMP Deviations: recalling drug products following an FDA inspection.
Class IIFDA: TerminatedAccord Healthcare, Inc.
DrugMar 8, 2023
Gabapentin Tablets, USP 600 mg, 500 tablets per bottle recall — FDA D-0354-2023
Presence of Foreign Tablets/Capsules: Pharmacist reported presence of some Gabapentin tablets 800 mg comingled in Gabapentin 600 mg 500 count bottles.
Class IIIFDA: TerminatedSciegen Pharmaceuticals Inc.
VehicleMar 1, 2023
CX-50 trailer hitch recall — NHTSA campaign 23V135000
Mazda North America Operations (Mazda) is recalling certain 2023 CX-50 vehicles equipped with a Mazda Genuine Accessory trailer hitch. The trailer hitch harness may detach and become…
trailer hitchMazda North American Operations
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 25 microgram/mL recall — FDA D-0335-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 50 microgram/mL recall — FDA D-0338-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
Dermoplast FIRST AID ANTIBACTERIAL SPRAY recall — FDA D-0329-2023
Subpotent Drug: Low assay observed in one of the two active ingredients during stability testing.
Class IIIFDA: TerminatedAdvantice Health, LLC
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 44 microgram/mL recall — FDA D-0337-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 13 microgram/mL recall — FDA D-0331-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 100 microgram/mL recall — FDA D-0332-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 88 microgram/mL recall — FDA D-0341-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 125 microgram/mL recall — FDA D-0333-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 37.5 microgram/mL recall — FDA D-0336-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 112 microgram/mL recall — FDA D-0342-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
DrugMar 1, 2023
TIROSINT - SOL (levothyroxine sodium) Oral Solution, 175 microgram/mL recall — FDA D-0334-2023
Subpotent Drug
Class IIFDA: TerminatedIBSA PHARMA Inc.
Browse by month
Recent recall archives
Browse recent months with enough recall history for useful comparison.
August 2026149 records · 4 categoriesJuly 2026371 records · 4 categoriesJune 2026375 records · 4 categoriesMay 2026340 records · 4 categoriesApril 2026415 records · 4 categoriesMarch 2026190 records · 4 categoriesFebruary 2026331 records · 4 categoriesJanuary 2026212 records · 4 categoriesDecember 2025389 records · 4 categoriesNovember 2025326 records · 4 categoriesOctober 2025455 records · 4 categoriesSeptember 2025285 records · 4 categories